Brian M. Silver to Join TScan Therapeutics as Chief Financial Officer

TScan Therapeutics will welcome Brian M. Silver as Chief Financial Officer on May 2, 2021. Brian will then resign as a Member of the Board of Directors. He is a seasoned finance executive with experience across both healthcare and investment banking. He is currently Chief Financial Officer and Head of Corporate Development for Freeline Therapeutics. Previously, he was a Partner with Perella Weinberg Partners, where he led the Biotechnology group. Prior to that, he had a 15-year tenure with Morgan Stanley, ultimately serving as a Managing Director in the Healthcare Group. He began his career as an Associate with Salomon Brothers.
 
TScan discovers and develops transformative T cell therapies (TCR-T) to treat solid tumors and hematologic malignancies, as well as other serious diseases. The company is based in Waltham, MA.